7:43 PM
 | 
Jun 08, 2016
 |  BC Extra  |  Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk),...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >